MELOXICAM (meloxicam) by Ascentage Pharma is cyclooxygenase inhibitors [moa]. First approved in 2004.
Drug data last refreshed 4d ago
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce inflammation and pain. It is indicated for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The oral suspension formulation was approved in 2004 and is now a generic medication.
As a maturing generic with approaching loss of exclusivity, meloxicam teams are likely focused on cost optimization and volume maintenance rather than growth initiatives.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days
A Study to Compare the Amount of Meloxicam in the Blood When it is Taken as Capsules or as Tablets
This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.
Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee
Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers
Worked on MELOXICAM at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Meloxicam roles are primarily operational and compliance-focused rather than strategic or brand-building. Career progression on this product is limited due to generic status, mature lifecycle, and commoditized market position; opportunities exist primarily in cost management and regulatory maintenance rather than revenue growth or innovation.